Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

" Evaluation of Erythropoietin Therapy in Patients With End-Stage Kidney Disease on Regular Hemodialysis: Hemoglobin Outcomes, and Metabolic Syndrome as a Risk Factor for Erythropoietin Resistance "

NCT06983756 is registered in ClinicalTrials.gov with Fayoum University as lead sponsor.

NCT NCT06983756
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06983756 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
" Evaluation of Erythropoietin Therapy in Patients With End-Stage Kidney Disease on Regular Hemodialysis: Hemoglobin Outcomes, and Metabolic Syndrome as a Risk Factor for Erythropoietin Resistance "
Lead sponsor
Fayoum University
Phase
Observational
Overall status
Not yet recruiting
Start date
June 1, 2025
Completion date
January 1, 2026
Enrollment
66 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

erythropoietin resistant anemia (epo resistant anemia)